NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $245.93 +2.11 (+0.87 %) (As of 02/19/2020 06:00 AM ET) Add Compare Today's Range$241.09Now: $245.93▼$246.0050-Day Range$217.83MA: $232.18▼$247.8152-Week Range$163.68Now: $245.93▼$249.00Volume1.31 million shsAverage Volume1.42 million shsMarket Capitalization$63.24 billionP/E Ratio54.53Dividend YieldN/ABeta1.45 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VRTX Previous Symbol CUSIP92532F10 CIK875320 Webhttp://www.vrtx.com/ Phone617-341-6100Debt Debt-to-Equity Ratio0.09 Current Ratio3.61 Quick Ratio3.49Price-To-Earnings Trailing P/E Ratio54.53 Forward P/E Ratio38.13 P/E Growth1.39 Sales & Book Value Annual Sales$4.16 billion Price / Sales15.19 Cash Flow$4.81 per share Price / Cash Flow51.16 Book Value$23.66 per share Price / Book10.39Profitability EPS (Most Recent Fiscal Year)$4.29 Net Income$1.18 billion Net Margins28.27% Return on Equity20.97% Return on Assets15.07%Miscellaneous Employees2,500 Outstanding Shares257,150,000Market Cap$63.24 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive VRTX News and Ratings via Email Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRTX Rates by TradingView Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions What is Vertex Pharmaceuticals' stock symbol? Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX." How will Vertex Pharmaceuticals' stock buyback program work? Vertex Pharmaceuticals announced that its Board of Directors has approved a stock repurchase program on Wednesday, July 31st 2019, which authorizes the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's leadership believes its shares are undervalued. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Thursday, January, 30th. The pharmaceutical company reported $1.70 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.21 by $0.49. The pharmaceutical company earned $1.41 billion during the quarter, compared to analysts' expectations of $1.01 billion. Vertex Pharmaceuticals had a net margin of 28.27% and a return on equity of 20.97%. Vertex Pharmaceuticals's revenue was up 62.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.30 EPS. View Vertex Pharmaceuticals' Earnings History. When is Vertex Pharmaceuticals' next earnings date? Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Vertex Pharmaceuticals. What guidance has Vertex Pharmaceuticals issued on next quarter's earnings? Vertex Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.1-5.3 billion, compared to the consensus revenue estimate of $4.87 billion. What price target have analysts set for VRTX? 26 analysts have issued 12 month price targets for Vertex Pharmaceuticals' stock. Their forecasts range from $183.85 to $300.00. On average, they expect Vertex Pharmaceuticals' share price to reach $252.41 in the next year. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals. What is the consensus analysts' recommendation for Vertex Pharmaceuticals? 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 7 hold ratings and 19 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals. What are Wall Street analysts saying about Vertex Pharmaceuticals stock? Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock: 1. Maxim Group analysts commented, "Vertex reported 2Q19 with cystic fibrosis (CF) revenue of $940M, beating consensus of $886.2M, up 25% y/y and 10% sequentially. All three approved CF drugs beat consensus; Kalydeco $262M vs. $254.5M, Orkambi $316M vs. $284.2M, and Symdeko $362M vs. $340.8M. Topline flowed through to the bottom line with $1.26 beating consensus of $1.07. Vertex ended the period with $4B in cash." (8/2/2019) 2. HC Wainwright analysts commented, "Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.94 discounted back to and (b) an NPV of $224/share (discount rate 11.0%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition." (8/1/2019) 3. Needham & Company LLC analysts commented, "Vertex reported $857M in 1Q19 WW Cystic Fibrosis sales, above our $842M and consensus $849M ests. Symdeko/ Symkevi is primary growth driver, as expected. Sales and OpEx guidance are unch. Non-GAAP EPS was $1.14, above our $1.04 and consensus $1.01 ests. Full data set from both triple drug CF Phase 3 programs expected in 2Q19 and mgmt reiterated plans to select best regimen for NDA and MAA submissions in 3Q19 and 4Q19, respectively. Vertex moving a new once- daily corrector (VX-121) into triple drug Phase 2 trial w/ VX-561/TEZ in hopes of even greater efficacy. VX-814 announced as first candidate for AAT . A Phase 1 trial is underway w/ more backup cmpds to move into clinic in 2019. NaV1.8 pain strategy update likely in 2H19. BUY. Vertex likely to hold strong competitive position in CF for several yrs." (5/1/2019) 4. According to Zacks Investment Research, "A significant increase in the eligible patient population for its CF drugs is driving sales growth at Vertex. Vertex’s third CF medicine, Symdeko, in a very short time, became the primary driver of growth in CF revenues in 2018. Vertex’s CF pipeline is also accelerating rapidly. However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Meanwhile, a switch in patient base to Symdeko from Orkambi is also hurting sales of the latter. Also, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have underperformed the industry this year so far." (3/8/2019) Has Vertex Pharmaceuticals been receiving favorable news coverage? Media headlines about VRTX stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vertex Pharmaceuticals earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave media stories about the pharmaceutical company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the near future. View News Stories for Vertex Pharmaceuticals. Who are some of Vertex Pharmaceuticals' key competitors? Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include Companhia de Saneamento Bsc DEDSP (SBS), NVIDIA (NVDA), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Incyte (INCY), Alphabet (GOOG), Micron Technology (MU), Gilead Sciences (GILD), Netflix (NFLX) and AbbVie (ABBV). Who are Vertex Pharmaceuticals' key executives? Vertex Pharmaceuticals' management team includes the folowing people: Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63) Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.28%), State Street Corp (4.43%), Capital World Investors (4.09%), Renaissance Technologies LLC (2.75%), Alliancebernstein L.P. (2.45%) and Capital International Investors (2.44%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, Thomas Graney, William D Young and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals. Which institutional investors are selling Vertex Pharmaceuticals stock? VRTX stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Westfield Capital Management Co. LP, Candriam Luxembourg S.C.A., Panagora Asset Management Inc., Commerzbank Aktiengesellschaft FI, DekaBank Deutsche Girozentrale and Marshall Wace North America L.P.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee. View Insider Buying and Selling for Vertex Pharmaceuticals. Which institutional investors are buying Vertex Pharmaceuticals stock? VRTX stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Renaissance Technologies LLC, Alliancebernstein L.P., Victory Capital Management Inc., Janus Henderson Group PLC, Assenagon Asset Management S.A., Victory Capital Management Inc. and Fred Alger Management LLC. View Insider Buying and Selling for Vertex Pharmaceuticals. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Vertex Pharmaceuticals' stock price today? One share of VRTX stock can currently be purchased for approximately $245.93. How big of a company is Vertex Pharmaceuticals? Vertex Pharmaceuticals has a market capitalization of $63.24 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 2,500 workers across the globe.View Additional Information About Vertex Pharmaceuticals. What is Vertex Pharmaceuticals' official website? The official website for Vertex Pharmaceuticals is http://www.vrtx.com/. How can I contact Vertex Pharmaceuticals? Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected] MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 1,381 (Vote Outperform)Underperform Votes: 769 (Vote Underperform)Total Votes: 2,150MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: Treasury Bonds
